Translating dosage compensation to trisomy 21.

Area of Science:

• Genetics
• Stem Cell Biology
• Genomic Medicine

Background:

• Down syndrome, caused by trisomy 21, presents significant medical and social challenges.
• Gene imbalance in trisomy 21 contributes to cellular pathologies.

Purpose of the Study:

• To investigate if manipulating the XIST gene can correct gene imbalance in Down syndrome.
• To develop a model for studying trisomy 21 and potential therapeutic strategies.

Main Methods:

• Utilized zinc finger nucleases for genome editing in Down syndrome pluripotent stem cells.
• Inserted an inducible XIST transgene into the DYRK1A locus on chromosome 21.
• Analyzed heterochromatin modifications, transcriptional silencing, and DNA methylation.

Main Results:

• Successfully created a 'chromosome 21 Barr body' via XIST-induced silencing.
• Observed rapid reversal of proliferation and neural rosette formation deficits.
• Established a system to study trisomy 21 pathologies without genetic noise.

Conclusions:

• Gene silencing of an extra chromosome 21 is feasible in vitro.
• This approach provides a model for human chromosome inactivation and trisomy 21 research.
• Demonstrates a potential first step towards 'chromosome therapy' for Down syndrome.